Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-04-10 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)
Regulatory Filings
2026-04-10 English
FDA Accepts NDA for TLX101-Px (Pixclara) 3 pages 227.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the FDA acceptance of a New Drug Application (NDA) for TLX101-Px (Pixclara®). It provides detailed information about the drug candidate, its regulatory status, clinical context, and company background. The document is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a significant development related to the company's product pipeline and regulatory progress. There is no financial data or quarterly/annual results presented. The document is longer than 5,000 characters and contains substantive content about the regulatory milestone. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-04-09 English
Ceasing to be a substantial holder 4 pages 210.9KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605 Corporations Act Section 671B' and is a 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests of a substantial shareholder, Citigroup Global Markets Australia Pty Limited, including dates and share amounts. The document includes legal references to the Corporations Act and securities lending agreements. It is a regulatory notice about changes in substantial shareholding, not a financial report, earnings release, or management discussion. It fits the definition of a Major Shareholding Notification, which involves notifications of changes in significant share ownership levels crossing thresholds.
2026-04-09 English
6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)
Regulatory Filings
2026-04-09 English
Telix Strengthens Board with Further Director Appointments 2 pages 206.4KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated April 9, 2026, announcing the appointment of two additional Non-Executive Directors to the Board. The content focuses exclusively on board changes and succession planning, detailing the backgrounds of the new directors and comments from the Interim Chair. There is no financial data, no discussion of financial results, no mention of shareholder votes, or other report types. The document is clearly an announcement of changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (8682 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2026-04-08 English
Application for quotation of securities - TLX 8 pages 26.0KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options exercised or convertible securities converted. The document includes specifics such as the number of securities, issue dates, and whether the securities are issued under employee incentive schemes. It does not contain financial statements, management discussion, or earnings data. It is not an announcement of a report publication but a regulatory filing related to securities quotation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.